Cell Therapy Manufacturing Market Size, Share, and Industry Analysis, By Type (Products {Instruments, Reagents, and Consumables}, and Services), By Cell Source (Autologous, Allogenic, and Xenogeneic), By Mode (Contract Manufacturing and In-house Manufacturing), By Application (Oncology, Autoimmune Disorders, and Others), By End-user (Pharmaceutical & Biotechnology Companies, CROs & CDMOs, and Others), and Regional Forecast, 2025-2032

Cell therapy manufacturing involves the production of therapeutic cells that can be used for various therapeutic applications, from cancers to monogenic diseases. Cell therapy manufacturing is applied in various medical fields due to its ability to regenerate and repair tissues. Cell therapy has many applications in oncology, hematology, tissue regeneration, cardiology, autoimmune disorders, and others.

Furthermore, the increasing prevalence of chronic diseases and autoimmune disorders has increased the demand for personalized treatment options, thus boosting the growth of the cell therapy manufacturing market.

• For instance, in May 2023, the National Center for Chronic Disease Prevention and Health Promotion reported that six in ten people in America at least have chronic diseases such as heart disease, stroke, cancer, or diabetes. Such many cases lead to an increased focus on personalized medicine options, thus boosting the market's growth.

There is an increasing demand for cell therapy manufacturing products, and the utilization of these products for research and development activities to launch advanced cell therapies for various diseases and conditions is propelling the growth of the cell therapy manufacturing market.

• For instance, in March 2022, Novartis partnered with Carisma Therapeutics to develop the HER 2 targeted CAR-M cell therapy for the treatment of solid tumors. Such initiatives undertaken by the key market players are leading toward the increasing adoption of cell therapy manufacturing products. It thus helps expand the market during the forecast period.

In addition, there are rising technological advances in the cell therapy manufacturing process and new software launches by the key players to automate the process and fulfill the increased demand for cell therapy-based products with purity and reliability. This is expected to expand the growth of the market during the forecast period.

• In January 2024, Thermo Fisher Scientific Inc. launched the Gibco Cell Therapy Systems (CTS) Cellmation Software to streamline and automate the cell therapy manufacturing process and deliver beneficial therapies rapidly and safely to patients—such launches aimed to boost the market’s growth.

During the COVID-19, the cell therapy manufacturing market was positively impacted. The positive impact of the market was due to the increasing number of cases of COVID-19 and the rise in the demand for the diagnosis and treatment of the infection. Thus, to fulfill the increased demand for vaccines during the pandemic, there was a surge in the demand for cell therapy manufacturing for the development of treatments and vaccines to battle SARS-CoV-2. Furthermore, the market stabilized during 2021, with the decrease in number of COVID-19 cases. However, the market has maintained its pre-pandemic position with increasing research and development activities for launching advanced treatment options for cell therapy.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Key Diseases, By Key Countries/Regions, 2023
• Technological Advancements in Cell Therapy Manufacturing
• Regulatory Guidelines for Cell Therapy Manufacturing
• New Product Launches By Key Players
• Key Industry Developments - Mergers, Acquisitions, and Partnerships.
• Impact of COVID-19 on the Market

Analysis by Product Type

Based on type, the cell therapy manufacturing market is segmented into products and services. The products segment held a considerable share of the market in 2023. The products’ segment comprises instruments, reagents, and consumables. The segment's dominance in the market is due to increasing research and development activities by the key players to launch cell therapy-based products. Also, the increasing prevalence of chronic and autoimmune diseases that require personalized treatment options eventually leads to the adoption of cell therapy manufactured products. It thus boosts the growth of the segment in the market.

Moreover, rising initiatives by the key players to expand the cell therapy manufacturing facilities to fulfill the patients' demand for cell therapy drugs are thus expected to boost the consumable segment growth in the market.

• For instance, in October 2023, Bayer AG announced the launch of a cell therapy manufacturing facility in California to advance regenerative medicines on a global level. The facility aimed to supply late-stage clinical trial material for bemdaneprocel cell therapy to treat Parkinson’s disease. Such launches led to the adoption of consumables for manufacturing cells, thus boosting the growth of the segment in the market.

Regional Analysis

To gain extensive insights into the market, Download for Customization

The global market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America held the highest share of the global cell therapy manufacturing market in 2023. The region's dominant position is due to the presence of key players in the market with advanced product offerings and contract manufacturing for cell therapy. Also, the region has advanced research and development facilities, stringent regulatory guidelines, and state-of-the-art pharmaceutical and biopharmaceutical manufacturing techniques. Such advancements boosted the region's growth in the cell therapy manufacturing market.

Additionally, the rising initiatives by the region's key players to expand the cell therapy manufacturing facilities for the development of advanced products in the region boosts the region's growth in the market.

• For instance, in April 2023, Bristol Myers Squibb announced the expansion of its cell therapy manufacturing network, enabling the in-house production of viral vectors for CAR T cell therapies and increasing the reliable supply for the company’s transformational cell therapies. Such advancements by the key players boost the region's growth in the market.

Additionally, Europe held a substantial share of the global cell therapy manufacturing market in 2023. The rise in the number of cases of chronic and autoimmune diseases augments the growth of the region in the market. Also, the presence of key players in the market with advanced product offerings in the region is anticipated to propel the region's growth.

Moreover, the strategic initiatives of key players to advance cell therapy manufacturing facilities in the region to offer advanced cell therapy products in the market, thus propelling the region's growth in the market.

• For instance, in September 2021, Autolus Therapeutics plc announced the approval for its new manufacturing facility in Stevenage, U.K., for developing next-generation T-cell therapies. Thus, such approvals and expansion of facilities boosted the adoption of the cell therapy manufacturing market in the region.

Key Players Covered

The report includes the profiles of key players, such as Merck KGaA, Cytiva, Thermo Fisher Scientific Inc., Sartorius AG, River Laboratories, Takara Bio Inc., AstraZeneca, Bayer Corporation, Cellares, and Catalent.

Key Industry Developments

• In February 2024, AstraZeneca announced an investment of USD 300.0 million in the Roseville cell therapy manufacturing facility to focus on producing and launching T-cell therapies for oncology indications.
• In August 2023, AGC Biologics announced the expansion of the Milan Cell & Gene Center GMP manufacturing site to fulfill the enormous clinical and commercial demand for cell therapy manufacturing products.
• In December 2022, Catalent announced the completion and inauguration of a commercial-scale cell therapy manufacturing facility in Gosselies, Belgium. The facility supports manufacturing autologous and allogeneic cell therapy through late-stage clinical and commercial-scale supply.